The role of [18F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of postchemotherapy residual masses in metastatic germ cell tumors - Prospects for management

World Journal of Urology

Volumn 22, Issue 2, 2004, Pages 132-139

  Pfannenberg, Anna C ^a   Oechsle, Karin ^a   Bokemeyer, Carsten ^a   Kollmannsberger, Christian ^a   Dohmen, Bernhard M ^a   Bares, Roland ^a   Hartmann, Jörg T ^a   Vonthein, Reinhard ^a   Claussen, Claus D ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

18F FDG PET; CT; Germ cell tumor; Residual masses; Tumor marker

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADULT; ARTICLE; BLOOD; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; GERM CELL TUMOR; HUMAN; METASTASIS; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADULT; FLUORODEOXYGLUCOSE F18; GERMINOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 12344326126     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00345-003-0392-6     Document Type: Article

References (30)

1. Bender H, Schomburg A, Albers P, Ruhlmann J, Biersack HJ (1997) Possible role of FDG-PET in the evaluation of urologic malignancies. Anticancer Res 17:1655-1660
2. Beyer J, Kramar R, Mandanas R, Linkesch W, Greinix A, Droz JP, Pico JL, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W (1997) High dose chemotherapy as salvage treatment in germ cell tumors. A multivariate analysis of prognostic variables. J Clin Oncol 14:2638-2645
3. Bokemeyer C (1998) Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors. Oncology 824:1-20
4. Bokemeyer C, Gerl A, Harstrick A, Schmoll HJ (1998) Therapie des fortgeschrittenen nichtseminomatösen Keimzelltumors. Onkologe 4:532-540
5. Bokemeyer C, Harstrick A, Beyer J, Metzner B, Ruther U, Hartmann JT, Holstein K, Derigs HG, de Wit R, Casper J, Schoffski P, Kuhrer I, Illiger HJ, Kempf B, Reichle A, Foller A, Hossfeld DK, Fischer JT, Berdel WE, Gerhartz HH, Kirchner H, Pfluger KH, Ostermann H, Kanz L, Schmoll HJ (1998) The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. Semin Oncol 25:24-32
6. Cremerius U, Effert PJ, Adam G, Sabri O, Zimny M, Wagenknecht G, Jakse G, Buell U (1998) FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med 39:815-822
7. Dohmen BM, Bares R, Gromius R, Harms W, Kamps H, Boekmann W, Jaske G, Buell U (1995) Improved staging of germ cell cancer after chemotherapy by FDG-positron-emission-tomography (PET). Eur J Nucl Med 22:804
8. Donohue JP, Rowland RG, Kopecky K, Steidle CP, Geier G, Ney KG, Einhorn L, Williams S, Loehrer P (1987) Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 137:1176-1179
9. Fossa SD, Aass N, Ous S, Hoie J, Stenwig AE, Lien HH, Paus E, Kaalhus O (1989) Histology of tumor residuals following chemotherapy in patients with advanced non-seminomatous testicular cancer. J Urol 142:1239-1242
10. Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE (1992) Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 10:569-573
11. Fox EP, Weathers TD, Williams SD, Loehrer PJ, Ulbright TM, Donohue JP, Einhorn LH (1993) Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11:1294-1299
12. Ganjoo KN, Rebecca JC, Sharma M, Einhorn LH (1999) Positron emission tomography scans in the evaluation of postchemo-therapy residual masses in patients with seminoma. J Clin Oncol 17:3457-3460
13. Hogeboom WR, Hoekstra HJ, Mooyaart EL, Sleijfer DT, Schraffordt Koops H (1993) Magnetic resonance imaging of retroperitoneal lymph node metastases of non-seminomatous germ cell tumors of the testis. Eur J Surg Oncol 19:429-437
14. Hopper KD, Singapuri K, Finkel A (2000) Body CT and oncologic imaging. Radiology 215:27-40
15. Hosten N, Stroszczynski C, Rick O, Lemke M, Felix R (1999) Retroperitoneale Rezidive nicht-seminomatöser Hodentumoren: Computertomographische Befunde vor retroperitonealer Lymphadenektomie. Fortschr Röntgenstr 170:61-65
16. Husband JE, Hawkes DJ, Peckham MJ (1982) CT estimations of mean attenuation values and volume in testicular tumors: a comparison with surgical and histologic findings. Radiology 144:553-558
17. International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification (1997): a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603
18. Javadpour N, Young JD (1992) Prediction of residual mass requiring resection after chemotherapy of stage III tetsticular cancer. A prospective study. Urology 40:7-8
19. Keyes JW (1995) SUV: Standard uptake or silly useless value? J Nucl Med 36:1836-1839
20. Lorigan JG, Eftekhari F, David CL, Shirkoda A (1988) The growing teratoma syndrome: an unusual manifestation of treated, nonseminomatous germ cell tumors of the testis. AJR 151:325-329
21. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
22. Motzer RJ, Gulati S, Crown JP, Weisen S, Doherty M, Herr H, Fair W, Sheinfeld J, Sogani P, Russo M, Bosl GJ (1992) High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 69:550-556
23. 18F]-2-fluoro-2-deoxy-D-Glukose (18FDG-PET) bei der Diagnostik retroperitonealer Lymphknotenmetastasen bei Hodentumoren. Urologe [A] 37:609-620
24. Nuutinen JM, Leskinen S, Elomaa I, Minn H, Varpula M, Solin O, Söderström KO, Joensuu H, Salminen E (1997) Detection of residual tumors in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer 33:1234-1241
25. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J (1996) Oncological applications of positron emission tomography with fluorine-18 fluordeoxyglucose. Eur J Nucl Med 23:1641-1674
26. Stephens AW, Gonin R, Hutchins GD, Einhorn LH (1996) Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 14:1637-1641
27. Steyerberg EW, Keizer HJ, Stoter G, Habbema JDF (1994) Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. Eur J Cancer 30:1231-1239
28. Stomper PC, Kalish LA, Garnick MB, Richie JP, Kantoff PW (1991) CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded? Radiology 180:711-714
29. Strauss LG (1996) Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnosis of oncological patients. Eur J Nucl Med 23:1409-1415
30. Wilson CB, Young HE, Ott RJ, Flower MA, Cronin BF, Pratt BE, McCready VR, Horwich A (1995) Imaging metastatic testicular germ cell tumors with 18-FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med 22:508-513